Korro Reports First Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire (Thu, 7-May 7:00 AM ET)
Korro to Participate in Upcoming Investor Conferences
Globe Newswire (Tue, 5-May 4:05 PM ET)
Korro Announces Oral and Poster Presentations at Upcoming Scientific Conferences
Globe Newswire (Thu, 16-Apr 7:30 AM ET)
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 10-Apr 4:05 PM ET)
Korro Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Globe Newswire (Thu, 12-Mar 4:05 PM ET)
Korro Raises $85 Million in Oversubscribed Private Placement to Advance RNA Editing Pipeline
Market Chameleon (Mon, 9-Mar 3:58 AM ET)
Korro Announces Oversubscribed $85 Million Private Placement
Globe Newswire (Mon, 9-Mar 7:30 AM ET)
Korro to Present at the TD Cowen 46th Annual Health Care Conference
Globe Newswire (Wed, 25-Feb 4:05 PM ET)
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.
Korro Bio trades on the NASDAQ stock market under the symbol KRRO.
As of May 14, 2026, KRRO stock price declined to $11.08 with 61,507 million shares trading.
KRRO has a beta of 2.14, meaning it tends to be more sensitive to market movements. KRRO has a correlation of 0.02 to the broad based SPY ETF.
KRRO has a market cap of $159.80 million. This is considered a Micro Cap stock.
Last quarter Korro Bio reported $0 in Revenue and -$1.69 earnings per share. This fell short of revenue expectation by $-650,512 and exceeded earnings estimates by $.22.
The top ETF exchange traded funds that KRRO belongs to (by Net Assets): VTI, IWM, VXF, LFSC, IWN.
KRRO has underperformed the market in the last year with a price return of -28.7% while the SPY ETF gained +28.7%. KRRO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -0.8% and -12.1%, respectively, while the SPY returned +10.0% and +5.1%, respectively.
KRRO support price is $10.68 and resistance is $11.72 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KRRO shares will trade within this expected range on the day.
